Quoin Wins EMA Orphan Drug Designation for QRX003
Quoin Pharmaceuticals received EMA orphan drug designation for QRX003 to treat Peeling Skin Syndrome. The company expects to start its first formal clinical trial for the condition before year-end.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.